Dublin, March 27, 2025 (GLOBE NEWSWIRE) — The “Paclitaxel Injection Market Report 2025″has been added to ResearchAndMarkets.com’s offering.
This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The paclitaxel injection market size has grown rapidly in recent years. It will grow from $6.02 billion in 2024 to $6.87 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to clinical research and trials, increasing incidence of cancer, patient awareness and education, globalization of pharmaceutical industry.
The paclitaxel injection market size is expected to see rapid growth in the next few years. It will grow to $11.17 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to personalized medicine approaches, biosimilar development, rising cancer burden in aging population, advancements in drug delivery systems, healthcare policy changes.
Major trends in the forecast period include integration of ai in oncology, telemedicine and remote healthcare services, technological innovations in drug delivery, integration of drug delivery technologies, rise of biosimilars.
The anticipated rise in breast cancer cases is poised to drive the growth of the paclitaxel injection market in the future. According to the American Cancer Society’s January 2023 estimate, approximately 297,790 new cases of invasive breast cancer are expected in the US, leading to an estimated 43,700 deaths in 2023. Thus, the increasing incidence of breast cancer is a significant factor propelling the growth of the paclitaxel injection market.
The increasing incidence of cancer is anticipated to drive the growth of the paclitaxel injection market in the future. For example, in May 2024, the National Cancer Institute, a US-based government agency focused on cancer research and training, projected that the global number of new cancer cases per year is expected to reach 29.9 million, along with 15.3 million cancer-related deaths by 2040. Therefore, the increasing incidence of cancer is propelling the growth of the paclitaxel injection market.
Leading companies in the paclitaxel injection market are focusing on developing innovative products using advanced materials, such as protein-bound particles, to deliver reliable services to consumers. For example, in April 2022, Apotex Corp, a US-based pharmaceutical firm, introduced Paclitaxel protein-bound particles for injection (albumin-bound), a generic alternative to Abraxane for the first-line treatment of locally advanced or metastatic non-small cell lung cancer and for metastatic breast cancer. This formulation is administered through intravenous infusion and was launched by American Regent, Inc. as an alternative to Abraxane.
Key players in the paclitaxel injection market are also concentrating on developing innovative products, such as albumin-bound paclitaxel solutions, to broaden treatment options for patients with specific cancer types, offering potentially life-extending therapies. For instance, in May 2023, American Regent, Inc., a US-based injectable manufacturer, launched Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), providing an alternative to Abraxane. This groundbreaking product functions as a microtubule inhibitor for the treatment of metastatic breast cancer, non-small cell lung cancer, and metastatic adenocarcinoma of the pancreas. Its significance lies in the potential to offer a life-extending treatment option for patients while aiding the company’s expansion into the oncology market, further underscoring the importance of domestically manufactured medications.
North America was the largest region in the paclitaxel injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paclitaxel injection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the paclitaxel injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Report Scope
Markets Covered:
1) By Type: Natural Paclitaxel; Semi-Synthetic Paclitaxel
2) By Drug Strength: 10mg Or mL; 20mg Or mL; 30mg Or mL
3) By Indication: Breast Cancer; Prostate Cancer; Testicular Cancer; Non-Small Cell Lung Cancer; Lung Cancer; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
5) By End User: Hospitals; Clinics; Cancer Research Institute
Subsegments:
1) By Natural Paclitaxel: Paclitaxel From Pacific Yew Tree; Paclitaxel From Other Natural Sources
2) By Semi-Synthetic Paclitaxel: Docetaxel (Taxotere); Other Semi-Synthetic Variants
Key Companies Profiled: Pfizer Inc.; Bristol-Myers Squibb Company; Fresenius Kabi Oncology Ltd.; Abbott Laboratories; Viatris Inc.
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2025-2029 |
| Estimated Market Value (USD) in 2025 | $6.87 Billion |
| Forecasted Market Value (USD) by 2029 | $11.17 Billion |
| Compound Annual Growth Rate | 12.9% |
| Regions Covered | Global |
Some of the major companies featured in this Paclitaxel Injection market report include:
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Fresenius Kabi Oncology Ltd.
- Abbott Laboratories
- Viatris Inc.
- Teva Pharmaceutical Industries Limited
- Sandoz International GmbH
- Hospira Inc.
- Dr. Reddy’s Laboratories Ltd.
- Apotex Inc.
- Intas Pharmaceuticals Ltd.
- Zydus Lifesciences Limited
- Torrent Pharmaceuticals Ltd.
- Luye Pharma Group
- Biological E Limited
- Alembic Pharmaceuticals Limited
- Khandelwal Laboratories Pvt. Ltd.
- Gland Pharma Limited
- Abraxis Bio Science Inc.
- Novasep Holding SAS
- Sagent Pharmaceuticals Inc.
- Hainan Haiyao Co Ltd.
- Accord Healthcare Ltd.
- Natco Pharma Limited
- Strides Pharma Science Limited
- Panacea Biotec Ltd.
- American Regent Inc.
- MSN Laboratories Pvt Ltd.
- Hetero Drugs Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/didwgr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Paclitaxel Injection Market
